Long-term efficacy and safety of lorlatinib versus alectinib in anaplastic lymphoma kinase-positive advanced/metastatic non-small cell lung cancer: matching-adjusted indirect comparison.

ABSTRACT: Aim: Lorlatinib demonstrated superior efficacy over alectinib as a first-line treatment for ALK-positive (ALK+) advanced/metastatic non-small cell lung cancer in a matching-adjusted indirect comparison (MAIC) using 3-year follow-up data from CROWN (lorlatinib). This study aimed to update these findings using the latest extended 5-year follow-up data from CROWN. Materials & methods: We conducted an anchored MAIC using data from CROWN and ALEX (alectinib). Patients were matched based on prespecified effect modifiers. We compared progression-free survival (PFS) using hazard ratios (HRs), restricted mean survival time and PFS probabilities and adverse events (AEs) using rate ratios and rate differences. PFS was analyzed in subgroups with and without baseline brain/CNS metastases.

SUBMITTER: Bauer T 

PROVIDER: S-EPMC12711101 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature